Clinical Trial Update: A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial update for MDV3100 (enzalutamide) in patients with castration-resistant (hormone-refractory) prostate cancer; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• MDV3100 (enzalutamide)

Snippet

Sponsor: Pfizer | Conditions: Prostate Cancer, Hormone Refractory Prostate Cancer | Phase 1 | Status: COMPLETED | Results posted: 2019-10-03